Weight-Loss Drug Boom in China, India, Brazil Could Create US$22bil Market by 2035
10 Articles
10 Articles
GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan says
The China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimates. Improving affordability, generic launches and wider access could drive adoption, though penetration remains low, particularly in India, where cost concerns and cultural resistance to injectable treatments remain key barriers.
The combined market for weight loss medicines in China, India and Brazil can grow to US$ 22 billion by 2035, compared to the current US$ 6.6 billion, estimated J.P. Morgan, as the improvement in financial accessibility and wider access drive adoption in populations of patients in largely unexplored. The market can grow at an annual rate of 15% by 2035, J.P. Morgan analysts said led by Yang Huang in a note this Friday, considering the high rates …
The potential market could grow at an annual rate of 15% by 2035
Coverage Details
Bias Distribution
- 60% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
